利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.023 秒)

    EXPRESSION SIGNATURE IN PERIPHERAL BLOOD FOR DETECTION OF AORTIC ANEURYSM
    3.
    发明申请
    EXPRESSION SIGNATURE IN PERIPHERAL BLOOD FOR DETECTION OF AORTIC ANEURYSM 审中-公开
    外周血中用于检测神经病变的表达标志

    公开(公告)号：US20130006342A1

    公开(公告)日：2013-01-03

    申请号：US13611240

    申请日：2012-09-12

    申请人： Yulei WANG ,  Catalin Barbacioru ,  Raymond R. Samaha ,  John A. Elefteriades

    发明人： Yulei WANG ,  Catalin Barbacioru ,  Raymond R. Samaha ,  John A. Elefteriades

    IPC分类号： C40B30/04 ,  A61F2/06 ,  C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/329

    摘要： We hypothesized that gene expression patterns in peripheral blood cells may correlate with TAA disease status, and carried out a comprehensive gene expression survey on peripheral blood cells obtained from TAA patients and normal individuals. A distinct gene expression profile in peripheral blood cells can classify TAA patients from normal individuals. The genes provided by the present teachings define a set of diagnostic markers, thus providing a blood-based gene expression test to facilitate early detection of TAA disease. Methods of distinguishing ascending from descending TAA are also provided, as are methods of distinguishing familial from sporadic TAA.

    摘要翻译： 我们假设外周血细胞中的基因表达模式可能与TAA疾病状态相关，并对从TAA患者和正常个体获得的外周血细胞进行综合基因表达调查。 外周血细胞中不同的基因表达谱可以分类来自正常个体的TAA患者。 本教导提供的基因定义了一组诊断标记，从而提供了一种基于血液的基因表达测试，以促进TAA疾病的早期检测。 还提供了区分上升TAA的方法，以及区分家族与散发性TAA的方法。

    Biomarkers for Use in Vessel Disorders
    6.
    发明申请
    Biomarkers for Use in Vessel Disorders 审中-公开
    用于血管障碍的生物标志物

    公开(公告)号：US20080305498A1

    公开(公告)日：2008-12-11

    申请号：US11577287

    申请日：2005-10-14

    申请人： Dianna M. Milewicz ,  William P. Dubinsky

    发明人： Dianna M. Milewicz ,  William P. Dubinsky

    IPC分类号： G01N33/554 ,  C12Q1/02

    CPC分类号： G01N33/6803 ,  G01N33/6848 ,  G01N2800/329

    摘要： The present invention relate to a method of diagnosing a subject having a vessel disorder. More particularly, a biological sample is obtained from a subject suspected of having a vessel disorder. A protein profile is determined or measured in the sample using procedures described herein, for example, mass spectrometry or immunodetection. The protein profile from the subject is compared to a protein profile in a healthy control, wherein an alteration in the levels of a protein of the profile in the subject compared to the healthy control is indicative of a vessel disorder.

    摘要翻译： 本发明涉及诊断具有血管病症的受试者的方法。 更具体地，从怀疑患有血管障碍的受试者获得生物样品。 使用本文所述的程序在样品中测定或测量蛋白质谱，例如质谱法或免疫检测。 将来自受试者的蛋白质谱与健康对照中的蛋白质谱进行比较，其中与健康对照相比，受试者中的轮廓蛋白水平的改变指示血管障碍。

    BIOMARKER FOR ABDOMINAL AORTIC ANEURYSM
    9.
    发明申请
    BIOMARKER FOR ABDOMINAL AORTIC ANEURYSM 审中-公开
    生物标记用于ABDOMINAL AORTIC ANEURYSM

    公开(公告)号：US20140308686A1

    公开(公告)日：2014-10-16

    申请号：US14349828

    申请日：2012-10-11

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： Hua Cai

    IPC分类号： C12Q1/00 ,  C12Q1/37

    CPC分类号： C12Q1/008 ,  C12Q1/37 ,  G01N33/5735 ,  G01N33/6893 ,  G01N2800/329 ,  G01N2800/50 ,  G01N2800/56 ,  Y10T436/147777

    摘要： Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA.

    摘要翻译： 用于检测apoE受试者的腹主动脉瘤（AAA）或AAA的倾向的方法，用于监测受试者AAA治疗效果的方法，以及评估AAA的严重程度或AAA风险的方法涉及测量量 的四氢生物蝶呤（H4B），并将其与标准或以前的测试样品中存在的H4B的量进行比较。 与标准相比，测试样品中存在的H4B量减少表示AAA或对AAA的倾向。 可以在第二时间点之前对受试者施用治疗，并且与第一测试样品相比，存在于第二测试样品中的H4B的量增加指示AAA的有效治疗。 可以鉴定候选人进一步测试或监测AAA，和/或AAA治疗。